Irbesartan treatment up-regulates hepatic expression of PPAR and its target genes in obese Koletsky (fa k /fa k) rats: A link to amelioration of hypertriglyceridaemia

British Journal of Pharmacology

Volumn 160, Issue 7, 2010, Pages 1796-1807

  Rong, X ^a   Li, Y ^a   Ebihara, K ^a   Zhao, M ^a   Kusakabe, T ^a   Tomita, T ^a   Murray, M ^b   Nakao, K ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

angiotensin II type 1 receptor; irbesartan; lipid; obesity; peroxisome proliferator activated receptor

Indexed keywords

ACYL COENZYME A OXIDASE; ADIPONECTIN; CARNITINE PALMITOYLTRANSFERASE; CD36 ANTIGEN; FATTY ACID; HORMONE; INSULIN; IRBESARTAN; LEPTIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDIDYMIS; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; FEEDING; FOOD INTAKE; GENE EXPRESSION; HOMEOSTASIS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KOLETSKY RAT; LIVER; MALE; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; WHITE ADIPOSE TISSUE;

ANIMALS; BIPHENYL COMPOUNDS; BLOTTING, WESTERN; GENE EXPRESSION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIVER; MALE; MUSCLE, SKELETAL; OBESITY; PPAR ALPHA; RATS; RATS, INBRED STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TETRAZOLES; TRIGLYCERIDES; UP-REGULATION;

EID: 77954343320     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00835.x     Document Type: Article

References (52)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2 S1 S209.
2. Bahadir O, Uzunlulu M, Oguz A, Bahadir MA (2007). Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 30:49 53.
3. Baron AD, Bretchel-Hook G, Johnson A, Hardin D (1992). Skeletal muscle blood flow: a possible link between insulin resistance and blood pressure. Hypertension 21:129 135.
4. Bays H, Mandarino L, DeFronzo RA (2004). Role of the adipocyte, free fatty acids and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463 478.
5. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M et al. (2004). Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993 1002.
6. Bergman RN, Ader M (2000). Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11:351 356.
7. Brunzell JD (2007). Clinical practice. Hypertriglyceridemia. N Engl J Med 357:1009 1017.
8. Cai XJ, Lister CA, Buckingham RE, Pickavance L, Wilding J, Arch JR et al. (2000). Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone. Brain Res Mol Brain Res 77:131 137.
9. Charles MA, Eschwe'ge E, Thibult N, Claude J-R, Warnet J-M, Rosselin GE et al. (1997). The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 40:1101 1106.
10. Chua SC, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L et al. (1996). Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271:994 996.
11. Cusin I, Rohner-Jeanrenaud F, Stricker-Krongrad A, Jeanrenaud B (1996). The weight-reducing effect of an intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats. Diabetes 45:1446 1450.
12. Di Filippo C, Lampa E, Tufariello E, Petronella P, Freda F, Capuano A (2005). Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes Res 13:1909 1914.
13. Festuccia WT, Blanchard PG, Turcotte V, Laplante M, Sariahmetoglu M, Brindley DN et al. (2009). The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake. Am J Physiol Regul Integr Comp Physiol 296:R1327 R1335.
14. Friedman JE, Ishizuka T, Liu S, Farrell CJ, Bedol D, Kaung HL et al. (1997). Reduced insulin receptor signaling in the obese spontaneously hypertensive Koletsky rat. Am J Physiol 273:E1014 E1023.
15. Ginsberg HN (1996). Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 45 (Suppl. 3 S27 S30.
16. Goossens GH, Blaak EE, Saris WH, van Baak MA (2004). Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 89:2690 2696.
17. Ichikawa Y (2007). Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 46:1331 1336.
18. Janiak P, Bidouard JP, Cadrouvele C, Poirier B, Gouraud L, Grataloup Y et al. (2006). Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats. Eur J Pharmacol 534:271 279.
19. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T (2007). Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14 200 patients. Cardiovasc Diabetol 6:12.
20. Koletsky S (1973). Obese spontaneously hypertensive rats-a model for study of atherosclerosis. Exp Mol Pathol 19:53 60.
21. Koletsky RJ, Ernsberger P (1992). Obese SHR (Koletsky rat): a model for the interactions between obesity and hypertension. In:Sassard J (ed.). Genetic Hypertension. John Libbey
22. Kouyama R, Suganami T, Nishida J, Tanaka M, Toyoda T, Kiso M et al. (2005). Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 146:3481 3489.
23. Krauss RM (2004). Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27:1496 1504.
24. Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, Hensler M et al. (2009). n-3 fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia 52:941 951.
25. Lorenzo O, Ruiz-Ortega M, Suzuki Y, Rupérez M, Esteban V, Sugaya T et al. (2002). Angiotensin III activates nuclear transcription factor-kappaB in cultured mesangial cells mainly via AT(2) receptors: studies with AT(1) receptor-knockout mice. J Am Soc Nephrol 13:1162 1171.
26. McGarry JD (2002). Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7 18.
27. Muñoz MC, Argentino DP, Dominici FP, Turyn D, Toblli JE (2006). Irbesartan restores the in-vivo insulin signaling pathway leading to Akt activation in obese Zucker rats. J Hypertens 24:1607 1617.
28. Muñoz MC, Giani JF, Dominici FP, Turyn D, Toblli JE (2009). Long-term treatment with an angiotensin II receptor blocker decreases adipocyte size and improves insulin signaling in obese Zucker rats. J Hypertens 27:2409 2420.
29. Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K (2009). Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol 50:1226 1235.
30. Nakayama S, Watada H, Mita T, Ikeda F, Shimizu T, Uchino H (2008). Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 31:7 13.
31. Oakes ND, Thalen PG, Jacinto SM, Ljung B (2001). Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50:1158 1165.
32. Parhofer KG, Münzel F, Krekler M (2007). Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study. Cardiovasc Diabetol 6:36.
33. Pravenec M, Landa V, Zidek V, Musilova A, Kren V, Kazdova L et al. (2001). Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats. Nat Genet 27:156 158.
34. Reddy JK, Hashimoto T (2001). Peroxisomal -oxidation and peroxisome proliferatoractivated receptor : an adaptive metabolic system. Annu Rev Nutr 21:193 230.
35. Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, Bull C et al. (2005). A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol 19:1593 1605.
36. Russell J, Kelly S, Vine D, Proctor S (2009). Irbesartan-mediated reduction of renal and cardiac damage in insulin resistant JCR: LA-cp rats. Br J Pharmacol 158:1588 1596.
37. Saloranta C, Groop L (1996). Interactions between glucose and NEFA metabolism in man. Diabetes Metab Rev 12:15 35.
38. Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004). Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109:2054 2057.
39. Sharma AM, Staels B (2007). Review: peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92:386 395.
40. Stienstra R, Duval C, Keshtkar S, van der Laak J, Kersten S, Müller M (2008). Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue. J Biol Chem 283:22620 22627.
41. Su X, Abumrad NA (2009). Cellular fatty acid uptake: a pathway under construction. Trends Endocrinol Metab 20:72 77.
42. Sugimoto K, Qi NR, Kazdová L, Pravenec M, Ogihara T, Kurtz TW (2006). Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47:1003 1009.
43. Takaya K, Ogawa Y, Hiraoka J, Hosoda K, Yamori Y, Nakao K et al. (1996). Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 14:130 131.
44. Toblli JE, Muñoz MC, Cao G, Mella J, Pereyra L, Mastai R (2008). ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. Obesity 16:770 776.
45. Tomiyama H, Yambe M, Yamada J, Motobe K, Koji Y, Yoshida M (2007). Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication. J Hypertens 25:883 889.
46. Villanueva CJ, Monetti M, Shih M, Zhou P, Watkins SM, Bhanot S et al. (2009). Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 50:434 442.
47. Wang T, Hartzell DL, Flatt WP, Martin RJ, Baile CA (1998). Responses of lean and obese Zucker rats to centrally administered leptin. Physiol Behav 65:333 341.
48. Wiernsperger N (1994). Vascular defects in the aetiology of peripheral insulin resistance in diabetes. A critical review of hypotheses and facts. Diabetes Metab Rev 10:287 307.
49. fak. Am J Physiol Regul Integr Comp Physiol 278:R1518 R1523.
50. Wu-Peng XS, Chua SC Jr., Okada N, Liu SM, Nicolson M, Leibel RL (1997). Phenotype of the obese Koletsky (f)rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (LEPR): evidence for deficient plasma-to-csf transport of leptin in both the Zucker and Koletsky obese rat. Diabetes 46:513 518.
51. Xu ZG, Lanting L, Vaziri ND, Li Z, Sepassi L, Rodriguez-Iturbe B et al. (2005). Upregulation of angiotensin II type 1 receptor, inflammatory mediators, and enzymes of arachidonate metabolism in obese Zucker rat kidney: reversal by angiotensin II type 1 receptor blockade. Circulation 111:1962 1969.
52. Yokozawa J, Sasaki T, Ohwada K, Sasaki Y, Ito JI, Saito T et al. (2009). Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of insulin resistance and hepatic steatosis. J Gastroenterol 44:583 591.